Radiopharm Theranostic initiated with a Buy at B. Riley

B. Riley initiated coverage of Radiopharm Theranostic (RADX) with a Buy rating and $15 price target Radiopharm in-licenses and incubates near-clinical-stage radiopharmaceutical assets for therapeutic and imaging purposes, the analyst tells investors in a research note. The firm believes the company’s clinical-stage pipeline is underappreciated by investors. Riley views RAD101 is well positioned to advance into a Phase III trial and be licensed out.